Clinical Trials Logo

Filter by:
NCT ID: NCT02289898 Completed - Pancreatic Cancer Clinical Trials

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

YOSEMITE
Start date: April 20, 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT02289690 Completed - Clinical trials for Small Cell Lung Cancer

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Start date: October 13, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).

NCT ID: NCT02289417 Completed - Ulcerative Colitis Clinical Trials

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

UC
Start date: January 8, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).

NCT ID: NCT02288585 Completed - Diabetes Mellitus Clinical Trials

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Start date: October 2014
Phase: N/A
Study type: Interventional

Double-blind, randomised, placebo-controlled, parallel group study with two intervention arms. The study will be conducted in 150 subjects and the primary objective is to show a fasting LDL-cholesterol and triglyceride lowering effect of plant sterols in subjects with established type 2 diabetes mellitus and subjects at high risk of developing type 2 diabetes.

NCT ID: NCT02288455 Completed - Clinical trials for Male Stress Urinary Incontinence

Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II)

RELIEFII
Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this investigation is to demonstrate the safety and efficacy of the GTU artificial urinary sphincter device in restoring continence in males who have confirmed urinary stress incontinence for a minimum of 12 months with primary etiology being radical prostatectomy or transurethral resection of the prostate (TURP).

NCT ID: NCT02287467 Completed - Influenza A Clinical Trials

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Start date: January 2015
Phase: Phase 3
Study type: Interventional

Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.

NCT ID: NCT02287233 Completed - Clinical trials for Acute Myelogenous Leukemia

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Start date: December 31, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and generate data to support a recommended Phase 2 dose (RPTD) in treatment-naïve participants with acute myelogenous leukemia (AML); and a Phase 2 part that will evaluate if the RPTD has sufficient efficacy and acceptable toxicity to warrant further development of the combination therapy.

NCT ID: NCT02285062 Completed - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

ROBUST
Start date: February 17, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.

NCT ID: NCT02283762 Completed - Clinical trials for Scleroderma, Systemic

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Start date: January 15, 2015
Phase: Phase 2
Study type: Interventional

To investigate if Riociguat is effective in the treatment of systemic sclerosis

NCT ID: NCT02283268 Completed - Clinical trials for Von Willebrand Disease

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Start date: April 1, 2015
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).